Remove Develop Remove Thousand Oaks Remove Venture Capital
article thumbnail

Xirrus Raises $10M More

socalTECH

Thousand Oaks-based wireless hardware provider Xirrus has raised yet another $10M in funding, according to a regulatory filing from the company Monday. Xirrus develops specialized, Wi-Fi hotspots specifically aimed at high density and high performance installations, such as campuses and public areas. Venture Partners.

article thumbnail

Atara Biotherapeutics Gets $38.5M

socalTECH

Thousand Oaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease. atara biotherapeutics venture capital renal disease lifescience amgen' READ MORE>>.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Amgen Backs Therapeutic Antibody Firm

socalTECH

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. According to Seattle-based Theraclone Sciences , Amgen Ventures was one of the investors in a $10.6M, Series B extension round for the company.

article thumbnail

ImmunGene Raises $9M

socalTECH

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. immungene venture capital biotech biotechnology cancer therapeutics'

article thumbnail

Amgen Re-Ups On miRagen

socalTECH

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , has re-upped on an investment in a biopharmaceuticals developing microRNA-based treatments for cardiovascular and muscle disease. and Broadview Ventures. miRagen is based in Boulder, Colorado.

article thumbnail

Amgen Backs Small Molecule Drug Firm

socalTECH

Amgen Ventures , the venture capital arm of Thousand Oaks-based Amgen , has backed the developer of a biopharmaceutical aimed at treating irritable bowel syndrome, kidney disease, and diabetes.

article thumbnail

Amgen Re-Ups Investment In Sutro Biopharma

socalTECH

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M